Sorafenib (Nexavar)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: BAY 43-9006, BAY 54-9085
  • Brand names: Nexavar, Sorafenat, Soranib

References

  1. 1.0 1.1 1.2 Sorafenib (Nexavar) package insert
  2. Sorafenib (Nexavar) package insert (locally hosted backup)
  3. Nexavar manufacturer's website
  4. Sorafenib (Nexavar) patient drug information (Chemocare)
  5. Sorafenib (Nexavar) patient drug information (UpToDate)